Daniel Amoako
Overview
Explore the profile of Daniel Amoako including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
160
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ko S, Radecki P, Belinky F, Bhiman J, Meiring S, Kleynhans J, et al.
Nat Commun
. 2024 Aug;
15(1):7240.
PMID: 39174553
Previous studies have linked the evolution of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genetic variants to persistent infections in people with immunocompromising conditions, but the processes responsible for these observations...
2.
Ko S, Radecki P, Belinky F, Bhiman J, Meiring S, Kleynhans J, et al.
bioRxiv
. 2024 Feb;
PMID: 38313289
Previous studies have linked the evolution of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) genetic variants to persistent infections in people with immunocompromising conditions, but the evolutionary processes underlying these observations...
3.
Gendrin A, Souliotis L, Loudon-Griffiths J, Aggarwal R, Amoako D, Desouza G, et al.
JMIR Form Res
. 2023 Jun;
7:e44876.
PMID: 37347514
Background: New drug treatments are regularly approved, and it is challenging to remain up-to-date in this rapidly changing environment. Fast and accurate visualization is important to allow a global understanding...
4.
Walaza S, Tempia S, von Gottberg A, Wolter N, Bhiman J, Buys A, et al.
Open Forum Infect Dis
. 2022 Dec;
9(12):ofac578.
PMID: 36570970
Background: Data on risk factors for coronavirus disease 2019 (COVID-19)-associated hospitalization and mortality in high human immunodeficiency virus (HIV) prevalence settings are limited. Methods: Using existing syndromic surveillance programs for...
5.
Khan K, Karim F, Ganga Y, Bernstein M, Jule Z, Reedoy K, et al.
Nat Commun
. 2022 Oct;
13(1):6057.
PMID: 36229444
No abstract available.
6.
Khan K, Karim F, Ganga Y, Bernstein M, Jule Z, Reedoy K, et al.
Nat Commun
. 2022 Aug;
13(1):4686.
PMID: 35948557
SARS-CoV-2 Omicron (B.1.1.529) BA.4 and BA.5 sub-lineages, first detected in South Africa, have changes relative to Omicron BA.1 including substitutions in the spike receptor binding domain. Here we isolated live...
7.
Khan K, Karim F, Cele S, Reedoy K, San J, Lustig G, et al.
Nature
. 2022 May;
607(7918):356-359.
PMID: 35523247
The extent to which Omicron infection, with or without previous vaccination, elicits protection against the previously dominant Delta (B.1.617.2) variant is unclear. Here we measured the neutralization capacity against variants...
8.
Cele S, Jackson L, Khoury D, Khan K, Moyo-Gwete T, Tegally H, et al.
medRxiv
. 2021 Dec;
PMID: 34909788
The emergence of SARS-CoV-2 Omicron, first identified in Botswana and South Africa, may compromise vaccine effectiveness and the ability of antibodies triggered by previous infection to protect against re-infection (1)....